AIRA Matrix is one of those companies that quietly built its technology long before artificial intelligence became a buzzword.
Founded in 2011 in Mumbai, the company began with a simple but powerful idea: many important medical decisions depend on analyzing images, and computers could help doctors do this faster and more consistently.
At that time, most of the work in pathology—the study of diseases through tissue samples—was still done manually. Doctors had to look at slides under microscopes and interpret what they saw, a process that takes time and can vary from one expert to another. AIRA Matrix saw an opportunity to bring machine learning into this space.
In its early years, the company focused on cancer diagnostics, particularly on improving how doctors interpret biopsy samples. Over time, it expanded its scope.
Today, AIRA Matrix works not just on diagnosis but also on areas like drug discovery and medical research. This evolution is important because it shows how the company moved from solving a single problem to building a broader platform that supports different parts of the healthcare system.
The company is led by Chaith Kondragunta, who has a background in analytics and data systems. His experience shaped the way AIRA Matrix approaches problems.
Instead of building tools that only work in a lab or a demo environment, the company has focused on making sure its technology fits into real-world medical workflows. This is harder than it sounds. Hospitals and labs have established ways of working, and any new technology must fit into those systems without slowing things down. AIRA Matrix built its products with this in mind, combining technical expertise with an understanding of how healthcare actually operates.
Funding for AIRA Matrix has followed a different path from many newer startups. Rather than raising large venture capital rounds, it has relied more on strategic backing and partnerships. One notable supporter has been the family office of Dilip Shanghvi, the founder of Sun Pharma. This kind of backing is significant because it comes from someone deeply connected to the pharmaceutical industry. It suggests that the company’s work is seen as valuable not just in theory but also in practice. The company has also been part of accelerator programs and collaborations with global healthcare players, which have helped it refine and deploy its technology.
At the heart of AIRA Matrix’s offering is its ability to analyze medical images using artificial intelligence. To understand why this matters, it helps to look at how pathology works today. When a patient undergoes a biopsy, a small sample of tissue is taken and examined under a microscope. A pathologist looks for patterns that indicate disease, such as cancer. This process requires years of training and careful attention, but it is also time-consuming and can be affected by human fatigue or differences in interpretation.
AIRA Matrix builds software that can look at these images and identify patterns automatically. For example, it can detect tumor regions or measure specific markers that help doctors decide how aggressive a cancer is. The system does not replace the doctor. Instead, it acts as a second pair of eyes, providing consistent measurements and highlighting areas that need attention. This helps reduce errors and speeds up the overall process.
Its tools can be used across diagnosis, research, and even drug development. For instance, pharmaceutical companies can use similar image analysis techniques to study how a drug affects tissue samples. By building a system that works across these different use cases, AIRA Matrix creates a more complete solution rather than a narrow tool.
Its systems have been deployed in hospitals, diagnostic labs, and research organizations across India, the United States, and Europe. In some cases, its tools have helped reduce the time it takes to generate pathology reports. Faster reports mean that patients can begin treatment sooner, which can make a significant difference in outcomes. The company has also worked with partners to improve the accuracy and consistency of diagnostic results, which is critical in diseases like cancer where treatment decisions depend on precise measurements.
Feedback from the market reflects both the promise and the challenges of this space. On the positive side, there is strong interest in tools that can reduce workload for doctors and improve diagnostic quality.
Many healthcare systems are also moving toward digital pathology, where slides are scanned and stored as images, making it easier to apply AI tools. However, adoption is not always fast. Hospitals are cautious when introducing new technology, especially when patient outcomes are involved. There are also regulatory requirements that must be met before such systems can be widely used.
AIRA Matrix has had to navigate these challenges by working closely with institutions and ensuring that its tools meet high standards.
Globally, AIRA Matrix is part of a larger movement to bring AI into healthcare. Companies in the United States, Europe, and Israel are working on similar problems, building tools for digital pathology and diagnostics. However, many of these companies focus on high-resource healthcare systems. AIRA Matrix has an advantage in understanding the needs of emerging markets, where resources may be limited and solutions need to be both effective and affordable.
This highlights the gap that AIRA Matrix is helping to fill. It is not just building advanced technology; it is making that technology usable in real-world settings where constraints are very different from those in developed markets.
-Our correspondent
